Morgan Stanley analyst Maxwell Skor downgraded Cidara Therapeutics (CDTX) to Equal Weight from Overweight with a $221.50 price target after the company agreed to be acquired by Merck (MRK) in an all-cash transaction for $221.50 per share.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDTX:
- Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!
- Cidara Therapeutics downgraded to Neutral from Overweight at JPMorgan
- Cidara downgraded to Sector Perform from Outperform at RBC Capital
- Midday Fly By: Walmart names new CEO, Merck acquires Cidara
- Cidara Therapeutics downgraded to Hold from Buy at Needham